

UNAUDITED NOTES TO FINANCIAL STATEMENTS

PART A - EXPLANATORY NOTES PURSUANT TO MFRS 134

1. BASIS OF PREPARATION

The interim financial report is unaudited and has been prepared in accordance with Malaysia Financial Reporting Standard ("MFRS") 134: Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2022. The explanatory notes attached to the interim financial statements explain events and transactions that are significant to the understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2022.

The audited financial statements of the Group for the year ended 31 December 2022 were prepared in accordance with Malaysian Financial Reporting Standards ("MFRS"). The significant accounting policies and method of computations adopted in the preparation of the financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 December 2022.

2. AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The preceding audited financial statements for the year ended 31 December 2022 were no subject to any qualification.

3. UNUSUAL ITEMS DUE TO THEIR NATURE, SIZE, OR INCIDENCE

There were no other unusual items affecting assets, liabilities, equity, net income, and cash flows during the current quarter under review.

4. CHANGES IN ESTIMATES

There were no changes in estimates that have had a material effect on the current quarter results.

5. DEBTS AND EQUITY SECURITIES

There were no issuances, cancellations, repurchases, resale, and repayments of debt and equity securities during the current quarter under review.

6. DIVIDENDS PAID

There was no dividend paid during the current quarter under review.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

7. TRADE AND OTHER RECEIVABLES

	As at 31-Mar-23 RM ('000)	As at 31-Dec-22 RM ('000)
Trade Receivables	()	
Third parties	25,608	20,491
Allowance for impairment loss	(742)	(742)
	24,866	19,749
Other Receivables		
Third and Related parties	2,732	2,560
Allowance for impairment loss	(2,449)	(2,449)
	283	111
Deposits and Prepayments	12,096	5,914
	37,245	25,774

a) Trade Receivables

The Group's normal trade credit term ranges from 30 to 90 days (2022: 30 to 90 days). Other credit terms are assessed and approved on a case-by-case basis. They are recognized at their original invoice amounts which represent their fair value on initial recognition.

The Group recognizes loss allowances for expected credit losses (ECLs) on trade receivables measured at amortised cost. The Group applies the simplified approach to provide ECLs for all trade receivables as permitted by MFRS 9.

The following table provides information about the exposure to credit risk and ECLs for trade receivables:

	As at 31-Mar-23 RM ('000)	As at 31-Dec-22 RM ('000)
Not past due	9,511	4,749
Past due:		
- Less than 30 days	2,788	1,150
- 31 to 60 days	1,762	2,811
- 61 to 90 days	500	4,642
- More than 90 days	11,047	7,139
-	25,608	20,491
Less: Loss allowance	,	,
- Collectively impaired	(136)	(136)
- Individually impaired	(606)	(606)
Trade Receivable net	24,866	19,749



UNAUDITED NOTES TO FINANCIAL STATEMENTS

Credit impaired

Trade receivables that are individually determined to be impaired at the reporting date relate to debtors that are in significant financial difficulties and have defaulted payments. These receivables are not secured by any collateral or credit enhancements.

8. SEGMENTAL INFORMATION

Healthcare: The business involves the supply of healthcare and related products, services to hospitals, healthcare centers and pharmacies. This includes the renal dialysis business which is for home and center-based treatments, serving both the domestic and export markets. This renal dialysis business was disposed of on 3 May 2021.

The Group's segmental revenue and profit/(loss) before tax (PBT/LBT) for the current quarter are as follow:

Revenue	Individual Quarter Ended		Cumulative Q	uarter Ended
	31-Mar-23	31-Mar-22	31-Mar-23	31-Mar-22
<u>Segment</u>	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Healthcare	14,428	18,295	14,428	18,295
Corporate	240	240	240	240
Elimination	(917)	(240)	(917)	(240)
Total	13,751	18,295	13,751	18,295
<u>(LBT)/PBT result</u> <u>Segment</u>	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Healthcare	(635)	939	(635)	939
Corporate	(196)	(29)	(196)	(29)
Elimination	-	-	-	-
Total	(831)	910	(831)	910

9. VALUATIONS OF PROPERTY, PLANT AND EQUIPMENT

The valuations of property, plant and equipment have been brought forward, without amendment from the previous annual financial statements of the Group.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

10. SIGNIFICANT EVENTS

There are no material events subsequent to the end of the reporting period under review that have not been reflected in the quarterly financial statements.

11. CHANGES IN COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the financial period ended 31 March 2023 and subsequent to financial period as of to date.

12. CONTINGENT LIABILITIES AND CONTINGENT ASSETS

There were no contingent liabilities or contingent assets for the Group for the current quarter under review.

13. CAPITAL COMMITMENTS

There were no material capital commitments at the financial period ended 31 March 2023.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

PART B – ADDITIONAL INFORMATION AS REQUIRED BY APPENDIX 9B OF BURSA MALAYSIA LISTING REQUIREMENTS

14. **PERFORMANCE REVIEW**

	Individual Quarter Ended 1Q 2023	Individual Quarter Ended 1Q 2022	Changes	Changes
	RM ('000)	RM ('000)	RM ('000)	%
Revenue	13,751	18,295	(4,544)	-25%
Profit before tax / (Loss before tax)	(831)	910	(1,741)	-191%

Revenue was lower by 25% from RM18.29m compared to Q1 last year mainly due to lower demand for certain products resulting from over-stocked positions and budget constraints from hospitals.

The lower sales revenue has resulted in a loss before tax of RM831k compared to a previous profit of RM910k. Increased procurement costs and competitive pricing has resulted in margin contraction for certain products especially products like disposable gloves.

15. COMPARISON WITH PRECEDING QUARTER'S RESULTS

	Reporting Quarter 1Q 2023	Previous Quarter 4Q 2022	Changes	Changes
	RM ('000)	RM ('000)	RM ('000)	%
Revenue	13,751	8,447	5,304	63%
Loss Before Tax (LBT)	(831)	(3,599)	(2,768)	77%

This quarter recorded an increase in revenue of 63% compared to the previous quarter and a loss before tax of RM831k, compared to a loss of RM3.6m due to impairment of receivables.

Losses incurred in this quarter is mainly due to lower margin for certain products due to competitive pricing particularly for products like disposable gloves.

16. COMMENTARY ON CURRENT YEAR PROSPECTS

While near-term headwinds such as from elevated inflation, high energy prices and rising interest rates this year still remains, current year prospects remain challenging in the face of reduced local demand for our products. The Company has expanded the product portfolio with our in-house brand to counter the margin contraction issue and is optimistic about the long term business prospects.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

17. PROFIT FORECAST

No profit forecast was announced hence there was no comparison between actual results and forecast.

18. TAXATION

No taxation is provided as the company incurred a loss during the quarter under review.

	Individual Quarter Ended		Cumulative Quarter Ended	
	31-Mar-23 31-Mar-22		31-Mar-23	31-Mar-22
	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Income tax credit/(expense)	-	(372)	-	(372)
Deferred tax assets/(liabilities)	-	-	-	-
Total	-	(372)	-	(372)

19. SALE OF UNQUOTED INVESTMENTS AND PROPERTIES

There was no sale of unquoted investments and properties during the current quarter under review.

20. MARKETABLE SECURITIES

There was no purchase or disposal of marketable securities during the current quarter under review.

21. CORPORATE PROPOSALS

There was no corporate proposal announced which remain uncompleted at the financial period ended 31 March 2023.

22. BANK BORROWINGS AND DEBT SECURITIES

The total bank borrowings of the Group as of financial period ended 31 March 2023 is as below :

	As at 31-Mar-23 RM ('000)	As at 31-Mar-22 RM ('000)
Current (Secured):		
Trade loan	3,258	1,207
Term loan	8,150	-
Total Bank Borrowings	11,408	1,207



UNAUDITED NOTES TO FINANCIAL STATEMENTS

23. CHANGES IN MATERIAL LITIGATION

The Board confirms that the Adventa Group is not engaged in any material litigation, claims or arbitration, either as plaintiff or defendant. The Board has no knowledge of any proceedings pending against Adventa Group or any facts likely to give rise to any proceeding which may have a material impact on the business or the financial position of Adventa Group.

24. EARNINGS PER SHARE

The basic and diluted earnings per share or the reporting period are computed as follows:

a. Basic

	Individual Quarter Ended		Cumulative Quarter Ended	
	31-Mar-23	31-Mar-22	31-Mar-23	31-Mar-22
Profit attributable to ordinary equity holders of the parent (RM '000)	(826)	700	(826)	700
Weighted average number of ordinary shares in issue (Unit '000)	152,786	152,786	152,786	152,786
Basic earnings per share (sen)	(0.54)	0.46	(0.54)	0.46

b. Diluted

There were no diluted earnings per share.

25. (LOSS) / PROFIT BEFORE TAX

(Loss) / profit before tax is stated after charging/(crediting):

	Individual Quarter Ended		Cumulative Quarter Ended	
	31-Mar-23 31-Mar-22 RM'000 RM'000		31-Mar-23	31-Mar-22
			RM'000	RM'000
Other income	47	49	47	49
Interest income	10	69	10	69
Net foreign exchange loss/(gain)	(37)	(108)	(37)	(108)
Interest expenses	(322)	(334)	(322)	(334)



UNAUDITED NOTES TO FINANCIAL STATEMENTS

26. REALISED AND UNREALISED PROFITS/LOSSES)

The breakdown of the retained profits of the Group as at reporting date into realised and unrealised profits/(losses) is as follows:

	As at 31-Mar-2023	As at 31-Mar-2022
Group's total Retained profits:	RM'000	RM'000
Realised	8,578	16,659
Unrealised	(3,118)	(3,931)
Total Realised and unrealised	5,460	12,728
Less: Consol adjustments	(827)	(1,429)
Retained profits	4,633	11,299

27. AUTHORISED FOR ISSUE

The interim financial statements were authorized for issue by the Board of Directors in accordance with a resolution of the directors on 18th May 2023.

By Order of the Board Adventa Berhad CHUA SIEW CHUAN Company Secretary MAICSA 0777689